Here’s another impromptu entry regarding a great new Web site I came across on Alzheimer’s disease that takes the issue to a whole new perspective: early-stage diagnosis. It’s called EarlySymptomsAlzheimers.com. The site is being launched by pharmaceutical giant Roche to commemorate Alzheimer’s Day, and, to my knowledge, it’s the first available Web site fully dedicated to early-stage (prodromal) Alzheimer’s disease. It’s definitely worth a look.
Targeting healthcare providers, patients and caregivers alike, the comprehensive Web site was developed to draw attention to the latest progress in exploring the value of early diagnosis and treatment for Alzheimer’s disease. This is important information to know, and to keep on hand, because research has shown that initial Alzheimer’s symptoms can occur up to 12 years before a formal diagnosis is made. The ability to recognize and identify early-stage symptoms can be a key advantage in the fight against this disease, so that therapeutic treatment can be administered before irreparable damage occurs. These early-stage symptoms can include significant memory loss, poor judgment and questionable decision-making, the kind of behavior that extends beyond the normal memory loss associated with natural aging.
The Web site offers an array of early Alzheimer’s-related information, in addition to social tools, such as videos and a blog, that help build online communities surrounding this universal subject. The site also provides visitors with a downloadable “Tracker Diary,” so that patients can monitor and document early symptoms of the disease. While Roche does not presently have any Alzheimer’s treatments on the market in the United States, the manufacturer has four products currently in development that are aimed at treating this disease. After review, I found the site to be a very straightforward online tool that didn’t seem to push any specific agenda save informing the public about early-stage symptoms. It’s a rich pool of helpful information for anyone thinking about, or having to interact with, this disease in any way.
Source: McKnight’s Long-Term Care News; November 2011; V32; #11